Mild positive. Boosts forecast.
• Revenue €5,477m +6% organic. In line with forecast.
• Adj EBIT €574m +6% cc. Margin 10.5%
• ND/E 3.0x stable. Target corridor 2.5-3.0x so not expected to rise. Has delevered by 100bps in 2yrs. Dividend was cut in 2024 but reinstated since. Policy is 30-40% NI payout.
• Raises EBIT growth forecast to 4-8% (from 3-7%)
• Kabi had 16.7% margin in Q3. Kabi margin expected at 16-16.5% for FY25. Helios at ~10%.
• Kabi biopharma had +37% growth driven by Tyenne.
• 15 product launches envisaged for FY25 in Pharma.
• Helios +4% organic growth. Quironsalud +7%.
• Has €500m Sep 26 Bond. The company says 1H26 debt has been addressed so this bond still needs to be refinanced.
(FREGR; Baa3/BBB/BBB-)
Find more articles and bullets on these widgets:
A bull cycle in USDCAD remains intact and last week’s break above the late September’s high, firms the bullish theme. This move higher also maintains the bullish price sequence of higher highs and higher lows. Note too that moving average studies are in a bull-mode position, highlighting a dominant uptrend. Sights are on 1.4019, a Fibonacci retracement point. On the downside, first key support lies at 1.3830, the 50-day EMA.
The AUDUSD uptrend remains intact and the pair is trading closer to its recent highs. Support to watch lies at the 50-day EMA, at 0.6560. A clear break of this average would signal scope for a deeper retracement and expose 0.6527 once again, a Fibonacci retracement. For bulls, a stronger reversal higher would refocus attention on 0.6707, the Sep 17 high. Initial resistance to watch is 0.6629, the Sep 30 and Oct 1 high.